News for hackers. Stuff that matters.
Re:Open-weight AI is having its Kubernetes moment. Let's not... by andsoitis on Saturday July 25, 2026 @01:45PM (#49049811)
Drug companies have a portfolio of compounds they research. Most don’t pay off, so R&D costs make their way into the pricing of those superstar and other drugs that do work. Also, timelines are pretty long.
Re:Open-weight AI is having its Kubernetes moment. Let's not... by mjhay on Saturday July 25, 2026 @01:59PM (#49049953)
Drug companies spend more on marketing than R&D
Re:Open-weight AI is having its Kubernetes moment. Let's not... by andsoitis on Saturday July 25, 2026 @02:47PM (#49050405)
So?
Re:Open-weight AI is having its Kubernetes moment. Let's not... by DennisP on Saturday July 25, 2026 @03:32PM (#49050742)
So pharmaceutical companies spend far less on marketing outside the US, partly because every other country besides New Zealand makes those incessant drug ads illegal, and partly because government negotiate prices and keep profit margins down. If the argument is that R&D costs are what make drugs expensive, then we could easily eliminate an even greater expense by just copying what other developed nations do.
Re:Open-weight AI is having its Kubernetes moment. Let's not... by andsoitis on Saturday July 25, 2026 @05:29PM (#49051792)
Don’t you think drug companies would be doing that (not advertise) if it would increase their profit?
Re:Open-weight AI is having its Kubernetes moment. Let's not... by DennisP on Saturday July 25, 2026 @05:56PM (#49052010)
Of course advertising increases their profit. It does that by increasing their revenue even more than the cost of the advertising.

For the rest of us, that giant increase in revenue is an increase in our healthcare costs.

Re:Open-weight AI is having its Kubernetes moment. Let's not... by andsoitis on Saturday July 25, 2026 @07:52PM (#49053064)
Ah so sounds like your logic is: ban advertising -> less costs -> less revenue & lower patient costs -> same profit.

I think I can spot a flaw in that logic.

Re:Open-weight AI is having its Kubernetes moment. Let's not... by DennisP on Saturday July 25, 2026 @08:28PM (#49053327)
That last step contradicts my previous comment.
Re:Open-weight AI is having its Kubernetes moment. Let's not... by ncallaway on Saturday July 25, 2026 @06:13PM (#49052192)
Well, R&D costs are able to make their way into the pricing due to the artificial supply restriction.

If supply was not artificially restricted (through patents), then competitors would be able to manufacture the drug, supply would expand, the price would collapse, and the original inventor would not be able to recover their R&D costs.